All News Top News Apr 11, 2019 Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States Learn More Share Top News Apr 10, 2019 Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility Learn More Share Top News Apr 8, 2019 Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019 Learn More Share Top News Apr 1, 2019 Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults Learn More Share Top News Apr 1, 2019 Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office Learn More Share
Top News Apr 11, 2019 Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States Learn More
Top News Apr 8, 2019 Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019 Learn More
Top News Apr 1, 2019 Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults Learn More
Top News Apr 1, 2019 Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office Learn More